NCT00355472 · OUTCOME

Incidence of Dose-Limiting Toxicities (DLTs)

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL · Source last updated 2012-10-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 28 days

What was measured

Subjects who were properly monitored for DLTs were to be analyzed to determine the number of subjects with a DLT by dose level.

Groups in this outcome

KW-0761

KW-0761 was administered 4 times at one-week intervals at a dose of 0.01, 0.1, 0.5 or 1.0 mg/kg in patients with CCR4 positive ATL or CCR4 positive PTCL

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
KW-0761	16

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
KW-0761	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1

denoms

counts
group Id
OG000
value
16
units
Participants

description

Subjects who were properly monitored for DLTs were to be analyzed to determine the number of subjects with a DLT by dose level.

groups

description
KW-0761 was administered 4 times at one-week intervals at a dose of 0.01, 0.1, 0.5 or 1.0 mg/kg in patients with CCR4 positive ATL or CCR4 positive PTCL
id
OG000
title
KW-0761

param Type

NUMBER

reporting Status

POSTED

time Frame

28 days

title

Incidence of Dose-Limiting Toxicities (DLTs)

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice